miR-340 Reverses Cisplatin Resistance of Hepatocellular Carcinoma Cell Lines by Targeting Nrf2-dependent Antioxidant Pathway

Shi, Liang; Chen, Zhanguo; Wu, Lili; Zheng, Jianjian; Yang, Jianrong; Chen, Xiaofei; Chen, Zengqiang; Cun-li, Liu; Chi, Sheng-Ying; Zheng, Jiaying; Huang, Haixia; Lin, Xiangyang; Zheng, Fang

doi:10.7314/apjcp.2014.15.23.10439

Cited by 80 publications

(52 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examination of the expression status, biological function and underlying mechanisms of specific miRNAs in gastric cancer can contribute to the identification of novel biomarkers and therapeutic targets in human gastric cancer. Previous studies have shown that miR-340 plays an important role in human cancers (8)(9)(10)(11)(12)(13)(14). It was found to inhibit the metastatic behavior of breast cancer cells (14) while it decreased the proliferation and promoted the cell apoptosis of prostate cancer cells (13,18).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have shown that miR-340 plays an important role in human cancers (8)(9)(10)(11)(12)(13)(14). It was found to inhibit the metastatic behavior of breast cancer cells (14) while it decreased the proliferation and promoted the cell apoptosis of prostate cancer cells (13,18). Moreover it was also found to modulate the stem-like cell function of glioma cells (10).…”

Section: Discussionmentioning

confidence: 99%

“…MicroRNA-340 (miR-340) has been found to play a critical role in human cancers, including breast (8,9), prostate (10,11), and esophageal cancer (12), hepatocellular carcinoma (13) and glioma (14). Functionally, miR-340 was found to inhibit the migration and invasion of breast cancer cells by inhibiting the Wnt pathway (8).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2

et al. 2016

View full text Add to dashboard Cite

Abstract. Aberrant expression and function of microRNAs (miRNAs) play a critical role in the development and progression of various human cancers including gastric cancer. However, the clinical significance and underlying mechanisms of miR-340 remain largely unknown in gastric cancer. In the present study, we demonstrated that the expression of miR-340 was aberrantly elevated in both gastric cancer tissues and cells. Moreover clinical association analyses disclosed that the elevated level of miR-340 was significantly associated with unfavorable clinicopathological characteristics of the gastric cancer patients, such as poor differentiation, large tumor size and advanced tumor-node-metastasis (TNM) stage. Gastric cancer patients with high expression of miR-340 had prominently shorter overall survival and disease-free survival. Functionally, forced expression of miR-340 promoted cell viability, proliferation, colony formation and cell cycle progression in the SGC-7901 cells, while miR-340 silencing reduced cell viability, proliferation, colony formation and cell cycle progression in MGC-803 cells. Furthermore, in vivo experiments indicated that miR-340 knockdown suppressed the tumor growth of MGC-803 cells. Notably, alteration of miR-340 expression affected the luciferase activity of wildtype 3'-UTR of cyclin G2 (CCNG2) and regulated CCNG2 abundance in gastric cancer cells, indicating that CCNG2 is a direct target of miR-340. Moreover, CCNG2 knockdown eradicated the effects of miR-340 silencing on gastric cancer cells. In conclusion, our data suggest that miR-340 may potentially serve as a novel prognostic biomarker and therapeutic target for gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Among them, miR-144 was demonstrated to act directly on Nrf2 39UTR and then modulate the expression of Nrf2 downstream targets and cellular glutathione levels (Sangokoya et al, 2010). Another study (Shi et al, 2014a) revealed that, compared with parental HepG2 cells, miR-340 was downregulated and Nrf2 was upregulated in cisplatin (CDDP)-resistant HepG2/CDDP cells. The effects of miR-340 mimics on Nrf2 and target gene (e.g., NQO1) expression were also demonstrated, which could be attenuated by miR-340 antagomir.…”

Section: Micrornas In Posttranscriptional Gene Regulationmentioning

confidence: 99%

MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy

Tian

et al. 2015

Drug Metabolism and Disposition

View full text Add to dashboard Cite

Knowledge of drug absorption, distribution, metabolism, and excretion (ADME) or pharmacokinetics properties is essential for drug development and safe use of medicine. Varied or altered ADME may lead to a loss of efficacy or adverse drug effects. Understanding the causes of variations in drug disposition and response has proven critical for the practice of personalized or precision medicine. The rise of noncoding microRNA (miRNA) pharmacoepigenetics and pharmacoepigenomics has come with accumulating evidence supporting the role of miRNAs in the modulation of ADME gene expression and then drug disposition and response. In this article, we review the advances in miRNA pharmacoepigenetics including the mechanistic actions of miRNAs in the modulation of Phase I and II drug-metabolizing enzymes, efflux and uptake transporters, and xenobiotic receptors or transcription factors after briefly introducing the characteristics of miRNA-mediated posttranscriptional gene regulation. Consequently, miRNAs may have significant influence on drug disposition and response. Therefore, research on miRNA pharmacoepigenetics shall not only improve mechanistic understanding of variations in pharmacotherapy but also provide novel insights into developing more effective therapeutic strategies.

show abstract

“…A number of contemporary studies have shown that altered miRNAs expression plays an important role in the chemoresistance of cancer cells by impairing cellular responses (Nagano et al, 2011;Wapinski et al, 2011). For instance, miR-340 is involved in cisplatin resistance of hepatocellular carcinoma cell lines due to regulating Nrf2-dependent antioxidant pathway (Shi et al, 2014). miR-130a plays an important role in gefitinib resistance in NSCLC by targeting Met .…”

Section: Introductionmentioning

confidence: 99%

Long Non-coding RNAs and Drug Resistance

Pan

Xie²,

Xu³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) are emerging as key players in gene expression that govern cell developmental processes, and thus contributing to diseases, especially cancers. Many studies have suggested that aberrant expression of lncRNAs is responsible for drug resistance, a substantial obstacle for cancer therapy. Drug resistance not only results from individual variations in patients, but also from genetic and epigenetic differences in tumors. It is reported that drug resistance is tightly modulated by lncRNAs which change the stability and translation of mRNAs encoding factors involved in cell survival, proliferation, and drug metabolism. In this review, we summarize recent advances in research on lncRNAs associated with drug resistance and underlying molecular or cellular mechanisms, which may contribute helpful approaches for the development of new therapeutic strategies to overcome treatment failure.

show abstract

miR-340 Reverses Cisplatin Resistance of Hepatocellular Carcinoma Cell Lines by Targeting Nrf2-dependent Antioxidant Pathway

Cited by 80 publications

References 13 publications

MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2

MicroRNA-340 promotes the tumor growth of human gastric cancer by inhibiting cyclin G2

MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy

Long Non-coding RNAs and Drug Resistance

Contact Info

Product

Resources

About